{
    "2021-10-06": [
        [
            {
                "time": "2021-10-06",
                "original_text": "复星医药新品进入II期临床 半年投入17.77亿研发“下猛药”",
                "features": {
                    "keywords": [
                        "复星医药",
                        "新品",
                        "II期临床",
                        "研发投入",
                        "17.77亿"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-06",
                "original_text": "陆家嘴财经早餐2021年10月6日星期三",
                "features": {
                    "keywords": [
                        "陆家嘴",
                        "财经早餐"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-10-06",
                "original_text": "复星医药VS恒瑞医药～恒瑞在行业还是有很高地位的，综合实力很强",
                "features": {
                    "keywords": [
                        "复星医药",
                        "恒瑞医药",
                        "行业地位",
                        "综合实力"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-10-06",
                "original_text": "复星医药VS西藏药业～复兴在西藏面前胜负比只有4:8？",
                "features": {
                    "keywords": [
                        "复星医药",
                        "西藏药业",
                        "胜负比",
                        "4:8"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}